Andrea Repaci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrea Repaci has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Dario de Biase
Solid Tumor Molecular Pathology Laboratory IRCCS Azienda Ospedaliero‐Universitaria di Bologna Bologna Italy
8 shared publications - Giovanni Tallini
Department of Medical and Surgical Sciences (DIMEC) University of Bologna Bologna Italy
8 shared publications - Thais Maloberti
Solid Tumor Molecular Pathology Laboratory IRCCS Azienda Ospedaliero‐Universitaria di Bologna Bologna Italy
7 shared publications - Sara Coluccelli
Solid Tumor Molecular Pathology Laboratory IRCCS Azienda Ospedaliero‐Universitaria di Bologna Bologna Italy
6 shared publications - Antonio De Leo
Solid Tumor Molecular Pathology Laboratory IRCCS Azienda Ospedaliero‐Universitaria di Bologna Bologna Italy
5 shared publications - Margherita Nannini
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
4 shared publications
Latest Publications
- Open Access
- 29 July 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 213, 104863
Corrigendum to “Exploring the role of TERT in thyroid cancer: A systematic review” [Crit. Rev. Oncol./Hematol. 213 (2025) 104792]
- 29 July 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 213, 104863
Open AccessCorrigendum to “Exploring the role of TERT in thyroid cancer: A systematic review” [Crit. Rev. Oncol./Hematol. 213 (2025) 104792]
- Open Access
- 5 June 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 213, 104792
Exploring the role of TERT in thyroid Cancer: A systematic review
- 5 June 2025
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 213, 104792
Open AccessExploring the role of TERT in thyroid Cancer: A systematic review
- Open Access
- 1 November 2024
- Published by Elsevier in Journal of Clinical & Translational Endocrinology
- Vol. 38, 100373
The right drug for the right patient at the right time with the right test in differentiated thyroid cancer (DTC)
- 1 November 2024
- Published by Elsevier in Journal of Clinical & Translational Endocrinology
- Vol. 38, 100373
Open AccessThe right drug for the right patient at the right time with the right test in differentiated thyroid cancer (DTC)
- 18 March 2024
- Published by Springer Nature in Endocrine
- Vol. 85 (2) , 1-16
Radioiodine whole body scan pitfalls in differentiated thyroid cancer
Purpose whole body scan (WBS) performed following diagnostic or therapeutic administration of I-131 is useful in patients with differentiated thyroid carcinoma. However, it can be falsely positive in various circumstances. We aimed to report a series of pitfalls in a clinical perspective. Methods A search in the database PubMed utilizing the following terms: “false radioiodine uptake” and “false positive iodine 131 scan” has been made in January 2023. Among the 346 studies screened, 230 were included in this review, with a total of 370 cases collected. Physiological uptakes were excluded. For each patient, sex, age, dose of I-131 administered, region and specific organ of uptake and cause of false uptake were evaluated. Results 370 cases of false radioiodine uptake were reported, 19.1% in the head-neck region, 34.2% in the chest, 14.8% in the abdomen, 20.8% in the pelvis, and 11.1% in the soft tissues and skeletal system. The origin of false radioiodine uptake was referred to non-tumoral diseases in 205/370 cases (55.1%), benign tumors in 108/370 cases (29.5%), malignant tumors in 25/370 cases (6.7%), and other causes in 32/370 cases (8.7%). Conclusions WBS is useful in the follow-up of patients with differentiated thyroid carcinoma, however it can be falsely positive in various circumstances. For this reason, it is critically important to correlate the scintigraphic result with patient’s medical history, serum thyroglobulin levels, additional imaging studies and cytologic and/or histologic result.
- 18 March 2024
- Published by Springer Nature in Endocrine
- Vol. 85 (2) , 1-16
Radioiodine whole body scan pitfalls in differentiated thyroid cancer
Purpose whole body scan (WBS) performed following diagnostic or therapeutic administration of I-131 is useful in patients with differentiated thyroid carcinoma. However, it can be falsely positive in various circumstances. We aimed to report a series of pitfalls in a clinical perspective. Methods A search in the database PubMed utilizing the following terms: “false radioiodine uptake” and “false positive iodine 131 scan” has been made in January 2023. Among the 346 studies screened, 230 were included in this review, with a total of 370 cases collected. Physiological uptakes were excluded. For each patient, sex, age, dose of I-131 administered, region and specific organ of uptake and cause of false uptake were evaluated. Results 370 cases of false radioiodine uptake were reported, 19.1% in the head-neck region, 34.2% in the chest, 14.8% in the abdomen, 20.8% in the pelvis, and 11.1% in the soft tissues and skeletal system. The origin of false radioiodine uptake was referred to non-tumoral diseases in 205/370 cases (55.1%), benign tumors in 108/370 cases (29.5%), malignant tumors in 25/370 cases (6.7%), and other causes in 32/370 cases (8.7%). Conclusions WBS is useful in the follow-up of patients with differentiated thyroid carcinoma, however it can be falsely positive in various circumstances. For this reason, it is critically important to correlate the scintigraphic result with patient’s medical history, serum thyroglobulin levels, additional imaging studies and cytologic and/or histologic result.
- 13 March 2024
- Published by Springer Nature in L'Endocrinologo
- p. 1-5
Tiroidite subacuta e vaccino anti SARS-CoV-2
- 13 March 2024
- Published by Springer Nature in L'Endocrinologo
- p. 1-5
Tiroidite subacuta e vaccino anti SARS-CoV-2
- 1 February 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (2) , 167-176
Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study
Purpose: The prognostic importance of RET and RAS mutations and their relationship to clinicopathologic parameters and outcomes in medullary thyroid carcinoma (MTC) needs to be clarified. Experimental design: A multicenter retrospective cohort study was performed utilizing data from 290 patients with MTC. The molecular profile was determined and associations were examined with clinicopathologic data and outcomes. Results: RET germline mutations were detected in 40 patients (16.3%). Somatic RET and RAS mutations occurred in 135 (46.9%) and 57 (19.8%) patients respectively. RETM918T was the most common somatic RET mutation (n=75). RET somatic mutations were associated with male sex, larger tumor size, advanced AJCC stage, vascular invasion (VI), and high IMTCGS grade. When compared with other RET somatic mutations, RETM918T was associated with younger age, AJCC (8th edition) IV, vascular invasion, extrathyroidal extension, and positive margins. RET somatic or germline mutations were significantly associated with reduced distant metastasis free survival on univariate analysis but there were no significant independent associations on multivariable analysis, after adjusting for tumor grade and stage. There were no significant differences in outcomes between RET somatic and RET germline mutations, or between RETM918T and other RET mutations. Other recurrent molecular alterations included TP53 (4.2%), ARID2 (2.9%), SETD2 (2.9%), KMT2A (2.9%), and KMT2C (2.9%). Among them, TP53 mutations were associated with decreased overall and disease-specific survival, independently of tumor grade and AJCC stage. Conclusions: RET somatic mutations were associated with high-grade, aggressive primary tumor characteristics, and decreased distant metastatic-free survival but this relationship was not significant after accounting for tumor grade and disease stage . RETM918T was associated with aggressive primary tumors but was not independently associated with clinical outcomes. TP53 mutation may represent an adverse molecular event associated with decreased overall and disease-specific survival in MTC but its prognostic value needs to be confirmed in future studies.
- 1 February 2024
- Published by SAGE Publications in Thyroid®
- Vol. 34 (2) , 167-176
Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study
Purpose: The prognostic importance of RET and RAS mutations and their relationship to clinicopathologic parameters and outcomes in medullary thyroid carcinoma (MTC) needs to be clarified. Experimental design: A multicenter retrospective cohort study was performed utilizing data from 290 patients with MTC. The molecular profile was determined and associations were examined with clinicopathologic data and outcomes. Results: RET germline mutations were detected in 40 patients (16.3%). Somatic RET and RAS mutations occurred in 135 (46.9%) and 57 (19.8%) patients respectively. RETM918T was the most common somatic RET mutation (n=75). RET somatic mutations were associated with male sex, larger tumor size, advanced AJCC stage, vascular invasion (VI), and high IMTCGS grade. When compared with other RET somatic mutations, RETM918T was associated with younger age, AJCC (8th edition) IV, vascular invasion, extrathyroidal extension, and positive margins. RET somatic or germline mutations were significantly associated with reduced distant metastasis free survival on univariate analysis but there were no significant independent associations on multivariable analysis, after adjusting for tumor grade and stage. There were no significant differences in outcomes between RET somatic and RET germline mutations, or between RETM918T and other RET mutations. Other recurrent molecular alterations included TP53 (4.2%), ARID2 (2.9%), SETD2 (2.9%), KMT2A (2.9%), and KMT2C (2.9%). Among them, TP53 mutations were associated with decreased overall and disease-specific survival, independently of tumor grade and AJCC stage. Conclusions: RET somatic mutations were associated with high-grade, aggressive primary tumor characteristics, and decreased distant metastatic-free survival but this relationship was not significant after accounting for tumor grade and disease stage . RETM918T was associated with aggressive primary tumors but was not independently associated with clinical outcomes. TP53 mutation may represent an adverse molecular event associated with decreased overall and disease-specific survival in MTC but its prognostic value needs to be confirmed in future studies.
- Open Access
- 26 January 2024
- Published by Springer Nature in Virchows Archiv
- Vol. 484 (2) , 321
Correction to: Molecular pathology of endocrine gland tumors: genetic alterations and clinicopathologic relevance
- 26 January 2024
- Published by Springer Nature in Virchows Archiv
- Vol. 484 (2) , 321
Open AccessCorrection to: Molecular pathology of endocrine gland tumors: genetic alterations and clinicopathologic relevance
- Open Access
- 18 December 2023
- Published by Springer Nature in Virchows Archiv
- Vol. 484 (2) , 289-319
Molecular pathology of endocrine gland tumors: genetic alterations and clinicopathologic relevance
Tumors of the endocrine glands are common. Knowledge of their molecular pathology has greatly advanced in the recent past. This review covers the main molecular alterations of tumors of the anterior pituitary, thyroid and parathyroid glands, adrenal cortex, and adrenal medulla and paraganglia. All endocrine gland tumors enjoy a robust correlation between genotype and phenotype. High-throughput molecular analysis demonstrates that endocrine gland tumors can be grouped into molecular groups that are relevant from both pathologic and clinical point of views. In this review, genetic alterations have been discussed and tabulated with respect to their molecular pathogenetic role and clinicopathologic implications, addressing the use of molecular biomarkers for the purpose of diagnosis and prognosis and predicting response to molecular therapy. Hereditary conditions that play a key role in determining predisposition to many types of endocrine tumors are also discussed.
- 18 December 2023
- Published by Springer Nature in Virchows Archiv
- Vol. 484 (2) , 289-319
Open AccessMolecular pathology of endocrine gland tumors: genetic alterations and clinicopathologic relevance
Tumors of the endocrine glands are common. Knowledge of their molecular pathology has greatly advanced in the recent past. This review covers the main molecular alterations of tumors of the anterior pituitary, thyroid and parathyroid glands, adrenal cortex, and adrenal medulla and paraganglia. All endocrine gland tumors enjoy a robust correlation between genotype and phenotype. High-throughput molecular analysis demonstrates that endocrine gland tumors can be grouped into molecular groups that are relevant from both pathologic and clinical point of views. In this review, genetic alterations have been discussed and tabulated with respect to their molecular pathogenetic role and clinicopathologic implications, addressing the use of molecular biomarkers for the purpose of diagnosis and prognosis and predicting response to molecular therapy. Hereditary conditions that play a key role in determining predisposition to many types of endocrine tumors are also discussed.
- Open Access
- 17 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 4057
Expanding the Spectrum of BRAF Non-V600E Mutations in Thyroid Nodules: Evidence-Based Data from a Tertiary Referral Centre
The BRAF p.V600E mutation represents the most specific marker for papillary thyroid carcinoma and is potentially related to aggressive behavior and persistent disease. BRAF alterations other than the p.V600E are less common in thyroid carcinoma and represent an alternative mechanism of BRAF activation with unclear clinical significance. The study aims to describe the frequency and clinicopathologic characteristics of BRAF non-V600E mutations in a large cohort (1654 samples) of thyroid lesions characterized by next-generation sequencing. BRAF mutations have been found in 20.3% (337/1654) of thyroid nodules, including classic (p.V600E) mutation in 19.2% (317/1654) of samples and non-V600E variants in 1.1% of cases (19/1654). BRAF non-V600E alterations include 5 cases harboring p.K601E, 2 harboring p.V600K substitutions, 2 with a p.K601G variant, and 10 cases with other BRAF non-V600E alterations. BRAF non-V600E mutations have been reported in one case of follicular adenoma, three cases of conventional papillary thyroid carcinoma, eight cases of follicular variant of papillary carcinomas, one case of columnar cell variant papillary thyroid carcinoma, one case of oncocytic follicular carcinoma, and two bone metastasis of follicular thyroid carcinoma. We confirm that BRAF non-V600E mutations are uncommon and typically found in indolent follicular-patterned tumors. Indeed, we show that BRAF non-V600E mutations can be found in tumors with metastatic potential. However, in both aggressive cases, the BRAF mutations were concomitant with other molecular alterations, such as TERT promoter mutation.
- 17 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 4057
Open AccessExpanding the Spectrum of BRAF Non-V600E Mutations in Thyroid Nodules: Evidence-Based Data from a Tertiary Referral Centre
The BRAF p.V600E mutation represents the most specific marker for papillary thyroid carcinoma and is potentially related to aggressive behavior and persistent disease. BRAF alterations other than the p.V600E are less common in thyroid carcinoma and represent an alternative mechanism of BRAF activation with unclear clinical significance. The study aims to describe the frequency and clinicopathologic characteristics of BRAF non-V600E mutations in a large cohort (1654 samples) of thyroid lesions characterized by next-generation sequencing. BRAF mutations have been found in 20.3% (337/1654) of thyroid nodules, including classic (p.V600E) mutation in 19.2% (317/1654) of samples and non-V600E variants in 1.1% of cases (19/1654). BRAF non-V600E alterations include 5 cases harboring p.K601E, 2 harboring p.V600K substitutions, 2 with a p.K601G variant, and 10 cases with other BRAF non-V600E alterations. BRAF non-V600E mutations have been reported in one case of follicular adenoma, three cases of conventional papillary thyroid carcinoma, eight cases of follicular variant of papillary carcinomas, one case of columnar cell variant papillary thyroid carcinoma, one case of oncocytic follicular carcinoma, and two bone metastasis of follicular thyroid carcinoma. We confirm that BRAF non-V600E mutations are uncommon and typically found in indolent follicular-patterned tumors. Indeed, we show that BRAF non-V600E mutations can be found in tumors with metastatic potential. However, in both aggressive cases, the BRAF mutations were concomitant with other molecular alterations, such as TERT promoter mutation.
- 13 February 2023
- Published by Springer Nature in L'Endocrinologo
- p. 1-6
Valutazione del grading nel carcinoma midollare tiroideo
- 13 February 2023
- Published by Springer Nature in L'Endocrinologo
- p. 1-6
Valutazione del grading nel carcinoma midollare tiroideo